Clinical Trial Update: A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing XY0206 to salvage chemotherapy in relapsed or refractory AML with FLT3-ITD mutation (ALIVE).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• XY0206

Snippet

Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd | Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation | Phase 3 | Status: NOT_YET_RECRUITING